NYC DOHMH Advisory about Tampered and/or Counterfeit Versions of Biktarvy and Descovy
On Aug. 5, 2021, Gilead Sciences, Inc. (Gilead) issued a Company Statement warning of tampered and/or counterfeit versions of HIV treatment regimen Biktarvy (bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg tablets) and HIV treatment and prevention medicine Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) in circulation in the […]
